Search results
Results from the WOW.Com Content Network
The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of September 16, 2024. Adam Spatacco has positions in Eli Lilly ...
Eli Lilly's sales and profit growth has been impressive. ... which some analysts predict could be worth $200 billion by 2031. Eli Lilly stock still has plenty of upside left.
Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity ...
Eli Lilly on Tuesday forecast 2024 profit above Wall Street estimates on soaring demand for Zepbound, its recently approved weight-loss drug, and said it would have new supply from expanded ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast ...
Eli Lilly’s stock price is riding a wave of optimism and strong earnings. ... J.P. Morgan Research forecasts that the GLP-1 market will exceed $100 billion by 2030, and total GLP-1 users may ...
Lilly also raised its 2024 profit forecast and said sales of Zepbound crossed $1 billion for the first time in a quarter since its launch in late 2023. ... for Eli Lilly's highly sought after ...